Natural history of hepatitis C

Journal of Hepatology, Supplement

Volumn 31, Issue 1, 1999, Pages 17-24

  Alberti, Alfredo ^a   Chemello, Liliana ^a   Benvegnù, Luisa ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Chronic hepatitis C; Hepatitis C; Natural history

Indexed keywords

ALANINE AMINOTRANSFERASE; VIRUS RNA;

ACUTE HEPATITIS; CANCER RISK; CELLULAR IMMUNITY; CHRONIC HEPATITIS; CONFERENCE PAPER; DISEASE ASSOCIATION; DISEASE COURSE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; MORBIDITY; MORTALITY; PRIORITY JOURNAL;

EID: 0033458046     PISSN: 01695185     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0168-8278(99)80369-9     Document Type: Conference Paper

References (47)

1. Bronowicki JP, Vetter D, Uhl G et al. Lymphocyte reactivity to hepatitis C virus antigens shows evidence for exposure to HCV
2. in HCV- seronegative spouses of HCV-infected patients. J Infect Dis 1997: 176: 518-522.
3. Koziel MJ, Wong DK, Dudley D et al. Hepatitis C virus specific cytolytic T lymphocytes and T helper responses in seronegative persons. J Infect Dis 1997: 176: 859-866.
4. Scognamiglio P, Accapezzato D, Casciaro MA, Caccaini A, Artini M, Bruno G, et al. Presence of effector CD8+ T cells in hepatitis C virus-exposed healthy seronegative donors. J Immunol 1999, in press.
5. Pagliaro L, Peri V, Linea C et al. Natural history of chronic hepatitis C: A systematic review. It. J Gastroenterol 1999, in press.
6. Giuberti T, Marin MG, Ferrari C et al. Hepatitis C virus viremia following clinical resolution of acute hepatitis C. J Hepatol 1994: 20:666-671.
7. Tremolada F, Casarin C, Alberti A et al. Long-term follow-up of NANB (type C) post-transfusion hepatitis. J Hepatol 1992: 16: 273-281.
8. Bortolotti F. (unpublished).
9. Gerlach JT, Diepolder HM, Gruener NH et al. Natural course of symptomatic acute hepatitis C. J Hepatol 1999: 30 (suppl.l): 120.
10. Seeff LB, Buskell-Bales Z, Wright EC et al. Long term mortality after transfusion associated NANB hepatitis. N Engl J Med 1992:327: 1906-1911.
11. Seeff LB, Hollinger B, Alter AJ. et al. Long-term morbidity of post-transfusion hepatitis C. Hepatology 1998: 28: 407A.
12. Barrera JM; Bruguera M, Ercilla MG, Gil C, Celis R, Gil MP et al. Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C. Hepatology 1995: 21: 639-644.
13. Di Bisceglie AM, Goodman ZD, Ishak KG et al. Long-term clinical and histopathological follow-up of chronic PT hepatitis. Hepatology 1991: 14: 969-974.
14. Korezt RL, Abbey H, Coleman E, Gitnick G. Non-A, non-B post-transfusion hepatitis - looking back in the second decade. Ann Intern Med 1993: 119: 110-115.
15. Kenny-Wlash E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999: 340: 1228-1233.
16. Poynard T, Bedossa P, Opolon P. Natural history of fibrosis progression in patients with chronic hepatitis C Lancet 1997: 349: 825-832.
17. Chemello L, Cavalletto L, Bernardinello E et al. Biochemical and histological activity predicts liver fibrosis progression in chronic hepatitis C. 1999, in press.
18. Vaquer P, Canet R, Llompart A, Riera J, Obrador A, Gayà J. Histological evolution of chronic hepatitis C. factors related to progression. Liver 1994: 14: 265-269.
19. Mattson L, Sonnenborg A, Weiland O. Outcome of acute symptomatic non-A, non-B hepatitis: a 13-year follow-up study of hepatitis C virus markers. Liver 1993: 13: 274-278.
20. Kao JH, Tsai SL, Chen PJ, Yang PM, Sheu JC, Lai MY et al. A clinicopathologic study of chronic non-A, non-B (type C) hepatitis in Taiwan. Comparison between post-transfusion and sporadic patients. J Hepatol 1994: 21: 244-249.
21. Takano S, Yokosuka o, Imazeki F, Tagawa M, Omata M. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology 1995: 21: 650655.
22. Wejstal R, Hermodsson S, Norkrons G et al. Long-term followup of chronic hepatitis NANB with special reference to hepatitis C. Liver 1991: 11: 143-148.
23. Hopf U, Moller B, Kuther D et al. Long-term follow-up of PT and sporadic chronic hepatitis NANB. J Hepatol 1990: 10: 6976.
24. Yousuf M, Nakano Y, Tanaka E, Sodeyama T, Kiyosawa K. Persistence of viremia in patients with type-C chronic hepatitis during long-term follow-up. Scand J Gastroenterol 1992: 27: 812816.
25. Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inowe O et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996: 23: 1334-1340.
26. Sanchez-Tapias JM, Lo lacono O. Storia naturale dell'infezione cronica da HCV: dall'epatite cronica alia cirrosi. In: Craxî A, Almasio P, Magrin S, editors. II virus dell'epatite C (HCV): 1'infezione e la maïattia. Vol. 2. Milan: Roche: 1995. p. 11-25.
27. Kobayashi M, Tanaka E, Sodeyama T, Urushihara A, Matsumoto A, Kiyosawa K. The natural course of chronic hepatitis C: a comparison between patients with genotypes 1 and 2 hepatitis C viruses. Hepatology 1996: 23: 695-699.
28. Takahashi M, Yamada G, Miyamoto R, Doi T, Endo H, Tsuji T. Natural course of chronic hepatitis C. Am J Gastroenterol 1993: 88: 240-243.
29. Shev S, Dhillon AP, Lindh M, Serèus Z, Wejstal R, Widell A et al. The importance of cofactors in the histological progression of minimal and mild chronic hepatitis C. Liver 1997: 17: 215-223.
30. Tong MJ, El-Farra NS, Raijes AR et al. Clinical outcomes after transfusion associated hepatitis C. N Engl J Med 1995: 332: 1463-1466.
31. Niederau C, Lange S, Heintges T et al. Prognosis of chronic hepatitis C: results of a large prospective cohort study. Hepatology 1998: 28: 1687-1695.
32. Kim WR, Poterucha JJ, Hermans JE et al. Cost-effectiveness of 6 and 12 months of interferon alpha therapy for chronic hepatitis C. Ann Intern Med 1997: 127: 866-874.
33. Bennett WG, Inoue Y, Beck JR et al. Estimates of the cost-effectiveness of a single course of interferon alpha 2b in patients with histologically mild chronic hepatitis C. Ann Int Med 1997: 127: 855-865.
34. Fattovich G., Giustina G., Degos F et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997: 1112: 463472.
35. Serfaty L, Aumaitre H, Chazouilleres O et al. Determinants of outcomer of compensated hepatitis C virus related cirrhosis. Hepatology 1998: 27: 1435-1440.
36. Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander J et al. The natural history of community-acquired hepatitis C in the United States. N Engl J Med 1992: 327: 18991905.
37. Delladetsima JK, Rassidakis G, Tassopoulos NC, Papatheodoridis GV, Smyrnoff T, Vafiadis I. Histopathology of chronic hepatitis C in relation to epidemiological factors. J Hepatol 1996: 24: 27-32.
38. Roudot-Thoraval F, Bastie A, Pawlotsky JM, Dhumeaux D. Epidemiological factors affecting the severity of hepatitis C virusrelated liver disease: a French survey of 6664 patients. The Study Group for the Prevalence and Epidemiology of Hepatitis C Virus. Hepatology 1997: 26: 485190.
39. Cramp ME, Carucci P, Underhill J, Naoumov NV, Williams R, Donaldson PT. Association between HLA class II genotype and spontaneous clearance of hepatitis C viraemia. J Hepatol 1998: 29: 207-213.
40. Alric L, Fort M, Izopet J, Vinel JP, Charlet JP, Selves J et al. Genes of the major histocompatibility complex class II influence the outcome of hepatitis C virus infection. Gastroenterology 1997: 113: 1675-1681.
41. Hohler T, Gerken G, Notghi A, Knolle P, Lubjuhn R, Taheri H et al. MHC class II genes influence the susceptibility to chronic active hepatitis C. J Hepatol 1997: 27: 259-264.
42. Pontisso P, Gerotto M, Benvegnù L, Chemello L, Alberti A. Coinfection with hepatitis B and C viruses. In: Schinazi RF, Sommadossi J-P, Thomas HC, editors. Therapies for Viral Hepatitis. 1998:417-422.
43. Soriano V, Rodriguez-Rosado R, Garcia-Samaniego J. Management of chronic hepatitis C in HIV-infected patients. AIDS 1999: 13: 539-546.
44. Benvegnù L, Pontisso P, Cavalletto D, Noventa F, Chemello L, Alberti A. Lack of correlation between hepatitis C virus genotype and clinical course of hepatitis C virus-related cirrhosis. Hepatology 1997: 25: 211-215.
45. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV related chronic disease. MMWR 1998: 47: 1-33.
46. Davis GL, Albright JE, Cook S et al. Projecting the future Healthcare burden from hepatitis C in the United States. Hepatology 1998: 28: 390A.
47. Deuffic S, Buffat 1, Poynard T, Valleron AJ. Modeling the hepatitis C virus epidemic in France. Hepatology 1999: 29: 1596-1601.